Clinical Trials Directory

Trials / Completed

CompletedNCT00002025

Open Label Ganciclovir Therapy for Sight- or Life-Threatening Cytomegalovirus Disease in the Immunocompromised Patient

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
—
Sponsor
Hoffmann-La Roche · Industry
Sex
All
Age
3 Months
Healthy volunteers
Not accepted

Summary

To make intravenous (IV) ganciclovir available to immunocompromised patients with life-threatening or sight-threatening Cytomegalovirus (CMV) infection, where the symptoms of the disease are too severe to allow admission to a controlled clinical study of ganciclovir therapy. To determine the safety and tolerance of 2 - 3 weeks induction course of ganciclovir IV followed by a maintenance course of ganciclovir IV for an indefinite duration. To tabulate the patient's clinical response.

Conditions

Interventions

TypeNameDescription
DRUGGanciclovir

Timeline

First posted
2001-08-31
Last updated
2005-06-24

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT00002025. Inclusion in this directory is not an endorsement.